Financials in USD. Standardized financial statements.
A compact view of how Global Pharmatech, Inc. turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2007 | FY 2006 | FY 2005 | FY 2004 |
|---|---|---|---|---|---|---|---|---|
| Revenue? | $310,895 | $66,375 | $58,585 | $0 | $2.82M | $2.38M | $3.09M | $1.56M |
| Revenue Growth? | +368.4% | +13.3% | 0.0% | -100.0% | +18.7% | -23.0% | +98.3% | 0.0% |
| Cost of Revenue? | $276,240 | $22,555 | $29,188 | $0 | $1.89M | $1.30M | $1.90M | $925,770 |
| Gross Profit? | $34,655 | $43,820 | $29,397 | $0 | $928,049 | $1.08M | $1.18M | $629,900 |
| Gross Margin? | +11.1% | +66.0% | +50.2% | 0.0% | +32.9% | +45.3% | +38.3% | +40.5% |
| Operating Expenses? | $102,471 | $183,394 | $51,200 | $113,279 | $3.42M | $2.56M | $1.56M | $1.06M |
| Operating Income? | -$67,815 | -$139,575 | -$21,800 | -$113,280 | -$2.49M | -$1.49M | -$379,100 | -$430,840 |
| EBITDA? | -$59,913 | $29,760 | $207,594 | -$113,280 | -$1.89M | -$736,876 | $846,225 | -$14,210 |
| Income Before Tax | -$67,728 | -$138,499 | -$21,004 | -$113,314 | -$2.50M | -$1.14M | $128,525 | $332,396 |
| Income Tax Expense | $0 | $0 | $0 | $0 | -$53,735 | $97,334 | $1,162 | $17,776 |
| Net Income? | -$67,728 | -$138,499 | -$21,004 | -$113,314 | -$2.45M | -$1.23M | $200,695 | $310,085 |
| EPS? | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.11 | $-0.06 | $0.01 | $0.00 |
| Diluted EPS? | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.11 | $-0.06 | $0.01 | $0.00 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality